The Society of Thoracic Surgeons 2008 Cardiac Surgery Risk Models: Part 2-Isolated Valve Surgery
ABSTRACT Adjustment for case-mix is essential when using observational data to compare surgical techniques or providers. That is most often accomplished through the use of risk models that account for preoperative patient factors that may impact outcomes. The Society of Thoracic Surgeons (STS) uses such risk models to create risk-adjusted performance reports for participants in the STS National Adult Cardiac Surgery Database (NCD). Although risk models were initially developed for coronary artery bypass surgery, similar models have now been developed for use with heart valve surgery, particularly as the proportion of such procedures has increased. The last published STS model for isolated valve surgery was based on data from 1994 to 1997 and did not include patients undergoing mitral valve repair. STS has developed new valve surgery models using contemporary data that include both valve repair as well as replacement. Expanding upon existing valve models, the new STS models include several nonfatal complications in addition to mortality.
Using STS data from 2002 to 2006, isolated valve surgery risk models were developed for operative mortality, permanent stroke, renal failure, prolonged ventilation (> 24 hours), deep sternal wound infection, reoperation for any reason, a major morbidity or mortality composite endpoint, prolonged postoperative length of stay, and short postoperative length of stay. The study population consisted of adult patients who underwent one of three types of valve surgery: isolated aortic valve replacement (n = 67,292), isolated mitral valve replacement (n = 21,229), or isolated mitral valve repair (n = 21,238). The population was divided into a 60% development sample and a 40% validation sample. After an initial empirical investigation, the three surgery groups were combined into a single logistic regression model with numerous interactions to allow the covariate effects to differ across these groups. Variables were selected based on a combination of automated stepwise selection and expert panel review.
Unadjusted operative mortality (in-hospital regardless of timing, and 30-day regardless of venue) for all isolated valve procedures was 3.4%, and unadjusted in-hospital morbidity rates ranged from 0.3% for deep sternal wound infection to 11.8% for prolonged ventilation. The number of predictors in each model ranged from 10 covariates in the sternal infection model to 24 covariates in the composite mortality plus morbidity model. Discrimination as measured by the c-index ranged from 0.639 for reoperation to 0.799 for mortality. When patients in the validation sample were grouped into 10 categories based on deciles of predicted risk, the average absolute difference between observed versus predicted events within these groups ranged from 0.06% for deep sternal wound infection to 1.06% for prolonged postoperative stay.
The new STS risk models for valve surgery include mitral valve repair as well as multiple endpoints other than mortality. Model coefficients are provided and an online risk calculator is publicly available from The Society of Thoracic Surgeons website.
- SourceAvailable from: Robert N Whistance
Aortic Valve, 12/2011; , ISBN: 978-953-307-561-7
- "Its development involved robust methodology in a large cohort of patients, but it has not been widely adopted, perhaps because of concerns over external validity in non-UK populations. The Society of Thoracic Surgeons has since built on the advantages of the Ambler score by producing a tool that assists in predicting nine different postoperative variables (STS- PROM; O'Brien et al., 2009). These are mortality, permanent stroke, renal failure, prolonged ventilation, deep sternal wound infection, reoperation, a composite endpoint of mortality and major morbidity, and short and prolonged postoperative stay. "
- [Show abstract] [Hide abstract]
ABSTRACT: The older adult population in the U.S. (>75 years old) is growing rapidly with seniors living well into their 80s and 90s. Incidence of calcific valvular stenosis increases with age, and as a result, the prevalence of calcific valvular aortic stenosis (AS) is increasing. Elderly people with symptomatic AS are particularly vulnerable to mortality as well as to reduced quality of life and increased dependency. Trans-catheter aortic valve replacement (TAVR) has revolutionized the treatment options for those with AS, especially in older adults who were previously deemed non-surgical or high risk surgical candidates. Several reports have shown improvements in longevity, functional class and quality of life following TAVR in older adults. Surgical techniques for aortic valve replacement have also improved. This review will discuss clinical elements of AS and the dynamic field of interventional treatment options.Current Cardiovascular Risk Reports 10/2012; 6(5). DOI:10.1007/s12170-012-0264-y
- [Show abstract] [Hide abstract]
ABSTRACT: Statine gelten heute als „Goldstandard“ in der primären und sekundären Prävention der koronaren Herzkrankheit. Für Patienten nach aortokoronarer Bypassoperation ist eine Statintherapie mit einer Reduktion der Bypassgraftsklerose und Risikoreduktion für das Auftreten von kardiovaskulären Ereignissen assoziiert. Darüber hinaus ist der unmittelbare Nutzen einer perioperativen Statintherapie für herzchirurgische Patienten im Fokus zahlreicher Studien. Es häuft sich sowohl die Erkenntnis, dass Patienten mit geplanter aortokoronarer Bypassoperation von einer perioperativen Statintherapie profitieren, die nicht allein auf den lipidsenkenden Effekt der Statintherapie zurückzuführen sind, als auch die Beobachtung, dass das perioperative Absetzen einer Statineinnahme Komplikationen begünstigen kann. Ob eine hochdosierte Statintherapie vor einer geplanten Bypassoperation eine Reduktion der postoperativen kardiozerebralen Komplikationrate erzielen kann, ist derzeit Gegenstand einer klinischen Studie. Im Gegensatz zu Patienten mit aortokoronarer Bypassoperation ist die aktuelle Evidenz für den routinemäßigen Einsatz von Statinen zur Prävention der biologischen Herzklappenprothesendegneration unzureichend.Zeitschrift für Herz- Thorax- und Gefäßchirurgie 12/2012; 26(6). DOI:10.1007/s00398-012-0947-1